Skip to main content
. 2020 Jun 8;75(8):623–631. doi: 10.1136/thoraxjnl-2019-214355

Figure 2.

Figure 2

Risk of bias for included trials. (van Meenen 2018 had stated in their protocol that an economic analysis would be performed. This however was not within the trial publication. Following correspondence with authors this was a shared decision by them and the editor of JAMA. This cost related data is currently being used to prepare a separate publication to be submitted aside of the main clinical results. therefore, we assessed rob for selective outcome reporting as low.) HTS, hypertonic saline; NAC, N-acetylcysteine.